Cas:145307-34-2 A-77636 (hydrochloride) manufacturer & supplier

Chemical Name:A-77636 (hydrochloride)

CAS.NO:145307-34-2

Synonyms:A-77636 hydrochloride hydrate;(1R,3S)-3-(1′-adamantyl)-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyran hydrochloride

Molecular Formula:C₂₀H₂₈ClNO₃

Molecular Weight:365.89400

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:515.3ºC at 760 mmHg

Density:N/A

Index of Refraction:

PSA:75.71000

Exact Mass:365.17600

LogP:4.75760

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like A-77636 hydrochloride hydrate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(1R,3S)-3-(1′-adamantyl)-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyran hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,A-77636 hydrochloride hydrate Use and application,(1R,3S)-3-(1′-adamantyl)-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyran hydrochloride technical grade,usp/ep/jp grade.

Related News: As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. A-77636 (hydrochloride) manufacturer Hong Kong confirmed its 14th coronavirus case late Saturday. The patient, an 80-year-old man, had traveled for a few hours to mainland China in early January, and later spent several days on a cruise ship in Japan with more than 3,000 passengers and employees. A-77636 (hydrochloride) supplier The company memo said Lilly couldn’t substantiate allegations that employees faced retaliation for refusing to make false statements. It did not address employees’ specific complaints that they faced retaliation for other reasons, other than to say it encouraged employees to “speak up.” A-77636 (hydrochloride) vendor As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. A-77636 (hydrochloride) factory As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL.